Evidence map›Paper›PMID 30922252›Full record

ArticleBMC cancer2019

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.

Daniel M Halperin, Lynn Huynh, Jennifer L Beaumont, Beilei Cai, Rachel H Bhak, Sahil Narkhede, Todor Totev, Mei S Duh, Maureen P Neary, David Cella

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  3. PROMIS-29 and EORTC QLQ-C30: an empirical investigation towards a common conception of health.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Daniel M HalperinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Lynn HuynhAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA, 02199, USA. Lynn.Huynh@analysisgroup.com.
Jennifer L BeaumontTerasaki Research Institute, 1018 Westwood Blvd., Los Angeles, CA, 90024, USA.
Beilei CaiNovartis Pharmaceuticals Corporation, One Health Plaza, 345/5120C, East Hanover, NJ, 07936-1080, USA.
Rachel H BhakAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA, 02199, USA.
Sahil NarkhedeAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA, 02199, USA.
Todor TotevAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA, 02199, USA.
Mei S DuhAnalysis Group, Inc., 111 Huntington Ave. 14th Floor, Boston, MA, 02199, USA.
Maureen P NearyNovartis Pharmaceuticals Corporation, One Health Plaza, 345/5120C, East Hanover, NJ, 07936-1080, USA.
David CellaDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 North Saint Clair St.19th Floor, Chicago, IL, 60611, USA.
Analysis Group (United States) · USNorthwestern University · USNovartis (Switzerland) · CHNovartis (United States) · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is limited information on changes over time in carcinoid syndrome (CS) symptoms and quality of life (QoL). This study assessed change in CS symptoms and QoL in patients treated with somatostatin analogs (SSAs) using the Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement Information System (PROMIS)-29 instruments.

methodsPatients ≥18 years old with CS symptoms and treated with SSA or non-SSA agents in the United States were recruited through a patient advocacy group to complete a two-part, anonymous online survey. Time point (T) 1 survey was fielded from July-October 2016, and T2 survey followed 6 months later. Clinical characteristics and SSA treatment duration were assessed at T1. FACT-G and PROMIS-29 QoL surveys were administered and CS symptoms were assessed at T1 and T2; proportions of patients not experiencing symptoms were compared by McNemar's test. Healthcare resource utilization (HRU) was assessed for the T1-T2 interval, and mean difference in QoL score from T1 to T2 by SSA duration was calculated.

resultsOf 117 participants at T1, 89 (76%) completed the T2 survey and served as the study sample; 11 (13%) were treated with SSAs for > 0-2 years, 37 (42%) for > 2-5 years, and 39 (45%) for > 5 years. A higher proportion of patients at T2 vs. T1 reported the following symptoms as not applicable: diarrhea (16% vs. 7%, p < 0.05), flushing (28% vs. 18%, p < 0.05), wheezing (78% vs 66%, p = 0.008). Most patients (89%) had a physical exam and a mean of 7.2 healthcare provider visits between T1 and T2. Patients treated with SSAs for ≤2 years had a mean positive change of 3.7 in their FACT-G total score between surveys, and 6.0 in an additional set of CS-specific questions. Patients receiving SSAs for > 2 years did not appear to associate with a clinically meaningful improvement in QoL score as assessed by FACT-G between T1 and T2; patients also had no clinically meaningful improvement as assessed by PROMIS-29.

conclusionsThere may be clinically important improvement in QoL as measured by FACT-G in patients in earlier years of receiving SSA, which may not appear in later years of SSA treatment.

Indexed as

AdultAgedAged, 80 and overFemaleHealth ResourcesHormone AntagonistsHumansMaleMalignant Carcinoid SyndromeMiddle AgedPatient Acceptance of Health CarePatient Reported Outcome MeasuresQuality of LifeSomatostatinYoung AdultHormone AntagonistsSomatostatinFACT-GHealthcare resource utilization(Limit = 3 to 10): carcinoid syndromeQuality of lifeSomatostatin analogs

Identifiers

PMID30922252
PMCPMC6437890
OpenAlexW2941878698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.